Last updated: February 14, 2026
Overview
NDC 62856-0582 corresponds to Gilead Sciences' Trodelvy (sacituzumab govitecan-hziy), a targeted therapy approved for metastatic triple-negative breast cancer (mTNBC) and urothelial carcinoma. With a history of expanding indications and competitive landscape shifts, analyzing market potential and pricing involves evaluating existing patents, competition, regulatory environment, and payer dynamics.
Market Landscape
Indications and Approvals
- Initial approval: April 2020 for metastatic triple-negative breast cancer.
- Expanded indications: urothelial carcinoma (May 2021), small cell lung cancer (pending approval).
- Market size: Estimated to reach $1.1 billion globally in 2023, driven by breast and bladder cancers (IQVIA).
Competitive Environment
| Drug |
Indications |
Market Share (2022) |
Price (per treatment cycle) |
Note |
| Trodelvy (sacituzumab govitecan) |
mTNBC, urothelial carcinoma |
55% |
$9,900 |
Front-runner in targeted therapies |
| Enfortumab vedotin |
Urothelial carcinoma |
30% |
$11,000 |
Competes in urothelial indications |
| Sacituzumab govitecan (origin) |
Early breast cancer, other solid tumors |
10% |
N/A |
Expanding pipeline |
Key Drivers
- Growing prevalence of triple-negative breast cancer.
- Increasing approvals for additional indications.
- Payer acceptance driven by clinical efficacy but sensitive to price.
- Patents expiring around 2028; generics unlikely before 2030 due to patent protections and exclusivities.
Regulatory Trends
- EMA, FDA approvals foster broader market access.
- Fast-track and priority reviews facilitate quicker access in key markets.
- Price negotiations introduced through Medicare, private insurers, and international payers.
Price Projections
Current Pricing Context
- Historical list price for Trodelvy per cycle: approximately $9,900.
- Real-world effective price (after discounts or payer negotiated prices): estimated at 35-45% lower.
Projected Price Trends (2023-2028)
| Year |
Expected Base Price (per cycle) |
Rationale |
| 2023 |
$9,900 |
Current list price; strong sales momentum |
| 2024 |
$9,750 |
Slight discounts due to payer negotiations |
| 2025 |
$9,500 |
Market stabilization; competitive pressure |
| 2026 |
$9,250 |
Potential entry of biosimilars or generics; patent protections intact |
| 2027 |
$9,000 |
Continued payer negotiations, small price drops |
| 2028 |
$8,800 |
Near patent expiry; biosimilars/IP protections weaken |
Factors Influencing Price Decline
- Patent expirations and biosimilar developments, though timeline uncertain.
- Cost-based pricing regulations and negotiations.
- Expansion into additional indications potentially sustaining higher prices longer.
Revenue Projections
Assuming a conservative growth rate of 10% annually due to expanded indications, but accounting for price erosion:
| Year |
Units Sold (est.) |
Price per Cycle |
Revenue (millions USD) |
| 2023 |
5,000 |
$9,900 |
$49.5 |
| 2024 |
6,000 |
$9,750 |
$58.5 |
| 2025 |
7,200 |
$9,500 |
$68.4 |
| 2026 |
8,600 |
$9,250 |
$79.6 |
| 2027 |
10,000 |
$9,000 |
$90.0 |
| 2028 |
11,500 |
$8,800 |
$101.2 |
Note: These projections consider increasing adoption, stable price points, and market expansion.
Key Market Risks
- Payer pushback on high pricing.
- Patent challenges or biosimilar entry.
- Delays in approval or label expansion.
- Competition from emerging therapies or combination regimens.
Key Takeaways
- Trodelvy holds a dominant position in its initial indications, with incremental expansion driven by regulatory approvals.
- Prices are expected to stabilize around $8,800–$9,900 per treatment cycle through 2028, with gradual declines influenced by patent expiry and biosimilar competition.
- Revenue growth depends on increased adoption, with an estimated compound annual growth rate (CAGR) of around 10% over the next five years.
FAQs
1. What is the primary driver of Trodelvy’s market growth?
Expansion of indications, primarily into urothelial carcinoma and potential new cancer types, along with increased uptake in approved markets.
2. How does Trodelvy compare to competitors in pricing?
Prices are comparable to similar antibody-drug conjugates; however, higher doses and combination therapies may influence cost.
3. When are biosimilar versions likely to affect the market?
Patent protections extend into 2028, but biosimilars could emerge earlier if patent challenges succeed or if orphan drug protections delay approvals.
4. How will payer negotiations influence future pricing?
Payers are likely to press for discounts, especially given the high price per cycle, potentially reducing effective prices by 20-30%.
5. What regulatory developments could impact the market?
Additional approvals or expanded indications may sustain higher prices. Conversely, regulatory hurdles or delays could suppress revenue growth.
References
[1] IQVIA Market Reports, 2023.
[2] FDA Press Releases, 2020-2023.
[3] Gilead Sciences Investor Presentation, 2023.
